​

B.Sc.Pharm - Hebrew University  2007
M.Sc. - Tel-Aviv University 2009
Ph.D. - Technion Institute   2015
Postdoctoral - MIT   2015-2019

Assistant Professor - Hebrew University   2019-2023

Associate Professor - Hebrew University- Present

 

Prof. Haitham Amal, is a world-leading expert in nitric oxide and brain disorders. He
is the head of The Laboratory of Neuromics, Cell Signaling, and Translational
Medicine. His lab leads multidisciplinary research combining OMICS technology with
systems biology together with biochemical, pharmacological, and behavioral tools.

Prof. Amal conducted his postdoctoral studies at the Massachusetts Institute of
Technology (MIT). Prof. Amal was a Senior Postdoctoral Associate at the Biological
Engineering Department at MIT and an affiliate in the Stanley Center for Psychiatric
Research at the Broad Institute of MIT and Harvard. 

Prof. Amal has received many awards/grants including the German DFG Grant, the
Israel Science Foundation grant, the prestigious Krill Prize administered by the Wolf
Foundation, US Department of Defense (DoD) grant, he was listed among the 40
under 40 most promising young people by The Marker Magazine, The Kaye
Innovation Award, the Prusiner Abramsky Neuroscience Award, Maof Research
Grant, the Golda Meir Lectureship Award, and the MIT-Technion Postdoc
Fellowship. 

Just recently, he won the US Eagles Autism Foundation Research Grant. Professor
Amal is the first international scientist to win this prestigious grant!

He was the first to show the first link between nitric oxide and autism spectrum
disorder (ASD) published in Advanced Science. Almetric (a weighted count of the
attention that a scholarly article has received) has tracked ~ 25 million papers and
his groundbreaking paper in Advanced Science was in the top 5% of all research
outputs ever tracked. The paper was on the news in many languages including
Spanish, Chinese, Portuguese, French, Italian, Hebrew, Arabic, and more.

One of the other Amal's discoveries showed pathological similarities between ASD
and Alzheimer’s pathologies both from the genetic and environmental backgrounds.

 
Prof. Amal Co-founded a Company, Point6 Bio Ltd, with the aim to develop diagnostic tool
for ASD based on simple blood and microbiome tests. He also Co-founded Company,
NeuroNOS, for developing a drug to treat autism and other neurological disorders.

​